Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
Delix Therapeutics has raised $25.0M in total funding. The most recent round was Series B. The last funding was announced in September 2025.
Delix Therapeutics's investors include RA Capital Management, Gaingels, Presight Capital, Artis Ventures, PsyMed Ventures.
Delix Therapeutics is headquartered in Boston, United States.
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
Delix Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Delix Therapeutics — Funding & Investors." VCBacked, September 10, 2025, https://www.vcbacked.co/company/delix-therapeutics. Accessed October 10, 2026.
VCBacked. (2025). Delix Therapeutics — Funding & Investors. Retrieved October 10, 2026, from https://www.vcbacked.co/company/delix-therapeutics
{{cite web |title=Delix Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/delix-therapeutics |website=VCBacked |access-date=October 10, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated